TABLE 6.
Summary of plasma-derived pharmacokinetics parameters: part 2 (idiopathic pulmonary fibrosis patients)
| TD139 | |||
| 0.3 mg | 3 mg | 10 mg | |
| Subjects | 5 | 5 | 5 |
| Cmax ng·mL−1 | |||
| Day 1 | 0.55±0.02 | 10.6±11.1 | 56.3±19.3 |
| Day 14 | 0.86±0.25 | 16.5±8.34 | 82.8±11.8 |
| Cmin ng·mL−1 | |||
| Day 1 | BLQ | 1.06±0.43 | 12.9±7.88 |
| Day 14 | BLQ | 1.48±0.51 | 14.7±8.64 |
| T1/2 h | |||
| Day 1 | ND | 6.36±2.09 | 9.69±1.70 |
| Day 14 | ND | 6.91±1.40 | 8.20±2.26 |
| AUC0−inf ng·h·mL−1 | |||
| Day 1 | ND | 69±50 | 921±479 |
| Day 14 | ND | 149±47 | 1150±462 |
Data are presented as n or mean±sd. Cmax: maximum plasma concentration; Cmin: plasma concentration at 24 h post-dose; T1/2: plasma half-life; AUC0-inf: area under the curve extrapolated to infinity from dosing time, based on the last observed concentration at 24 h post-dose; BLQ: below limit of quantification (0.5 ng·mL−1); ND: not determined due to insufficient data.